Sodelglitazar
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| [4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid[1] | |
| Clinical data | |
| Pregnancy cat. | N/A |
| Legal status | Investigational |
| Identifiers | |
| CAS number | 447406-78-2 |
| ATC code | ? |
| Chemical data | |
| Formula | ? |
Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline.[2] While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.[3]
Safety
Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.[4]
See also
References
- ↑ US Patent No. 7105551 "96 dpi image of original patent USPTO 7105551". Retrieved 2 Apr 2013.
- ↑ Liu, X. Y.; Wang, R. L.; Xu, W. R.; Tang, L. D.; Wang, S. Q.; Chou, K. C. (2011). "Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar". Protein and peptide letters 18 (10): 1021–1027. doi:10.2174/092986611796378701. PMID 21592078.
- ↑ Eckhard Ottow, Hilmar Weinmann (2008). Nuclear Receptors as Drug Targets. Wiley. pp. 380–. ISBN 978-3-527-31872-8. Retrieved 2 April 2013.
- ↑ "A randomised,double-blind, parallel group, placebo-controlled, multicentre study to evaluate the safety, tolerability and efficacy of oral GW677954 capsules 2.5mg, 5mg, 10mg and 20mg a day for 24 weeks in overweight dyslipidaemic subjects". GlaxoSmithKline. 2013-09-01.
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.